Neutropenia and management of cancer patients during the COVID-19 pandemic

Authors

  • O.V. Ponomariova Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • P.V. Petelskyi Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • A.S. Kasianenko Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • T.A. Horbatiuk Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • M.M. Nosko Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • N.V. Banakhevych Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • A.N. Kliusov Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • A.V. Kondratenko Municipal Non-Profit Enterprise “Kyiv City Clinical Oncology Center”, Kyiv, Ukraine
  • A.V. Kapinos Municipal Non-Profit Enterprise “Kyiv Regional Hospital 2” Kyiv, Ukraine

DOI:

https://doi.org/10.22141/2663-3272.4.2.2021.238668

Keywords:

COVID-19, cancer screening, neutropenia

Abstract

The COVID-19 pandemic has significantly affected the management of patients with cancer. Due to the quarantine restrictions imposed to some extent around the world, it was necessary to modify treatment regimens by reducing the number of sessions of chemotherapy and radiation therapy, as well as by postponing surgery. The volume of cancer screening has also been reduced. All this, from our point of view, in the long run may not have a very positive effect on the course of treatment and prognosis of cancer. Therefore, doctors today are constantly faced with the task of maintaining the effectiveness of treatment of malignant neoplasms, on the one hand, and reducing the risk of coronavirus — on the other, because, according to many sources, cancer patients are at risk of adverse COVID-19 course. This is especially true for patients with chemotherapy-induced neutropenia. In this article we wanted to demonstrate the latest approaches to the management of cancer patients in this difficult period. We also considered the options for wider use of granulocyte colony-sti­mulating factors to prevent neutropenia in the COVID-19 era. It is still controversy about this in the medical scientific community. Unfortunately, the data available today are not enough to make unambiguous statements about a particular patient management, but by analyzing the large number of publications made during the pandemic year, as well as updated National Comprehensive Cancer Network guidelines, we were able to answer most of the questions that interest us.

References

Beeching N.J., Fletcher T.E., Fowler R. Coronavirus disease 2019 (COVID-19). BMJ Best Practices. BMJ Publishing Group, 2020.

Beeching N.J., Fletcher T.E., Fowler R. Complications. Coronavirus disease 2019 (COVID-19). BMJ Best Practice.

Mahumud R.A., Kamara J.K., Renzaho A.M.N. The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis. Infection. 2020 Aug 19. 1-21.

Saini K.S., Tagliamento M., Lambertini M. et al. Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies. Eur. J. Cancer. 2020. 139. 43-50. doi: 10.1016/j.ejca.2020.08.011.

Banfill K., Price G., Wicks K. et al. Changes in management for patients with lung cancer treated with radical radiotherapy during the first wave of the COVID-19 pandemic in the UK (COVID-RT Lung). European Lung Cancer Virtual Congress 2021 (25–27 March).

Patt D., Gordan L., Diaz M., Okon T., Grady L., Harmison M., Markward N., Sullivan M., Peng J., Zhou A. Impact of COVID-19 on Cancer Care: How the Pandemic Is Delaying Cancer Diagnosis and Treatment for American Seniors. JCO Clin. Cancer Inform. 2020 Nov. 4. 1059-1071. doi: 10.1200/CCI.20.00134. PMID: 33253013. PMCID: PMC7713534.

Jee J., Foote M.B., Lumish M. et al. Chemotherapy and ­COVID-19 Outcomes in Patients with Cancer. J. Clin. Oncol. 2020 Oct 20. 38(30). 3538-3546. doi: 10.1200/JCO.20.01307. Epub 2020 Aug 14. PMID: 32795225. PMCID: PMC7571792.

Lasagna A., Zuccaro V., Ferraris E., Rizzo G., Tancredi R.J., Pedrazzoli P. How to Use Prophylactic G-CSF in the Time of ­COVID-19. JCO Oncology Practice. 2020. 16. 11. 771-772.

Tralongo A.C., Danova M. Granulocyte colony-stimulating factors (G-CSF) and Covid-19: a double-edged sword? Infez. Med. 2020 Sep 1. 28(3). 459-460. PMID: 32920586.

Cooksley T., Font C., Scotte F., Escalante C., Johnson L., Anderson R., Rapoport B. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of ­COVID-19: a MASCC position paper. Support Care Cancer. 2021 Feb. 29(2). 1129-1138. doi: 10.1007/s00520-020-05906-y. Epub 2020 Nov 23. PMID: 33230644. PMCID: PMC7682766.

https://www.nccn.org/covid-19/pdf/HGF_COVID-19.pdf

Published

2021-08-19

Issue

Section

Practicing Physician